Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.
Innovative Injectable and Cellular Therapies: A New Era in Knee Osteoarthritis Treatment for 2024
July 1, 2025
No Comments
Discover the latest advances in knee osteoarthritis (OA) treatment with regenerative and injectable therapies in 2024. Unlike traditional approaches that only manage symptoms, innovative options like platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), and amniotic allografts aim to repair joint damage and restore lost cartilage. Learn how these therapies promote tissue regeneration, reduce inflammation, and may help slow or reverse OA progression—offering longer-lasting relief and improved mobility. The article explores how regenerative medicine compares to standard treatments, highlights current research findings, and explains the importance of personalized care. Stay informed about the future of OA management and emerging options that bring new hope for joint health and lasting pain reduction.
